Status:
UNKNOWN
Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer
Lead Sponsor:
Cancer Research UK
Conditions:
Prostate Cancer
Eligibility:
MALE
Phase:
NA
Brief Summary
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It ma...
Detailed Description
OBJECTIVES: * To identify the molecular and pathophysiological changes which occur during the early stages of androgen deprivation (AD) and during emerging castration-resistant prostate cancer. * To ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Meets 1 of the following criteria:
- High clinical suspicion of prostate cancer, based on an abnormal digital rectal examination and PSA (\> 20 ng/mL)
- Newly diagnosed, castration-resistant prostate cancer
- Clinical stage ≥ T2c disease
- Significant tumor volume on initial diagnostic biopsy (\> 50% of cores)
- Likely to receive androgen deprivation therapy for prostate cancer
- PATIENT CHARACTERISTICS:
- No contraindication to transrectal needle biopsy
- No contraindication to MRI or prostate needle biopsy
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00967954
Start Date
September 1 2008
Last Update
January 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Research UK at Cambridge Research Institute
Cambridge, England, United Kingdom, CB2 0RE